ZIVO Bioscience, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John Bernard Payne
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 East Long Lake Road Bloomfield Hills MI United States of America 48304
- IPO Date
- Dec 15, 2003
- CIK
- 0001101026
- Website
- zivobioscience.com
- Similar Companies
- Business
- ZIVO Bioscience, Inc. (ZIVO) develops and commercializes nutritional compounds and bioactive molecules derived from its proprietary algal strains for applications in human and animal health; the Michigan-based biotechnology company, founded in 1994 and headquartered in Troy, operates primarily through licensing its intellectual property portfolio encompassing algae cultures, extracts, derivatives, and production techniques to manufacturers in the nutraceutical, agtech, and pharmaceutical sectors. Core products target human dietary supplements and nutraceuticals including algal biomass for immune modulation, skin health, anti-aging, and food ingredients; animal feed additives and therapeutics such as immune-modulating solutions for poultry coccidiosis prevention and treatment, bovine mastitis management, and canine joint health; and emerging pharmaceuticals for human use, with additional focus on sustainable non-GMO protein sources, oligosaccharides for infant formula, and productivity enhancers for livestock and aquaculture. Geographically, ZIVO serves global markets with emphasis on North America, advancing its pipeline through strategic collaborations including a partnership with a leading global animal health company for poultry immune-enhancing compounds and a 42-day confirmatory study on coccidiosis treatments in broiler chickens; recent developments encompass uplisting to OTCQB, a $1 million bridge financing for validation studies, applications for substantial USDA grants targeting avian influenza innovations, plans for a new avian influenza study with the University of Delaware, establishment of the ZIVOLife Agtech business unit, and positive efficacy results from coccidiosis challenge trials confirming non-antibiotic alternatives.
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
ZIVO Bioscience Provides Special Letter to Shareholders
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH)
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
ZIVO Bioscience to Present at The Microcap Conference 2025
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
ZIVO Bioscience Announces Uplisting to OTCQB Market
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience Announces Reverse Stock Split
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News